about
Introduction to the new International Classification of Headache DisordersMedical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in ItalyThe Neuropharmacology of Cluster Headache and other Trigeminal Autonomic CephalalgiasPlacebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacksAlpha-dihydroergocryptine and predictive factors in migraine prophylaxisFamily-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disordersSPG3A: An additional family carrying a new atlastin mutationHypnic headache: PSG evidence of both REM- and NREM-related attacksEffects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception: possible implications in migraine prophylaxisFamilial basilar migraine associated with a new mutation in the ATP1A2 geneA novel ATP1A2 mutation in a family with FHM type IIDihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trialA new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptylineBotulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystoniaActive music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation.Active music therapy and Parkinson's disease: methods.Italian guidelines for primary headaches: 2012 revised versionPeripheral and central activation of trigeminal pain pathways in migraine: data from experimental animal models.Bromocriptine test in the evaluation of patients with syncope of unknown aetiology. A case-control study.Neuroendocrine data in chronic post-traumatic headache.The effects on the central nervous system of nitroglycerin--putative mechanisms and mediators.CSF and plasma levels of pro-opiomelanocortin-related peptides in reversible ischaemic attacks and strokes.Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts.Effects of anandamide in migraine: data from an animal model.Experimental models for the study of cluster headache.Neurophysiological approach to the study of cluster headache.Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.Evaluation of thermal water in patients with functional dyspepsia and irritable bowel syndrome accompanying constipation.Functional changes of the basal ganglia circuitry in Parkinson's disease.Unilateral headaches and their relationship with cervicogenic headache.Whiplash injuries: clinical picture and diagnostic work-up.Current methods for cervical spine movement evaluation: a review.Migraine as a complex disease: heterogeneity, comorbidity and genotype-phenotype interactions.Effect of nitric oxide donors on the central nervous system--nitroglycerin studies in the rat.Diagnostic and therapeutic errors in cluster headache: a hospital-based studyThe potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.Diagnostic issues in chronic daily headache.The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache.New appendix criteria open for a broader concept of chronic migraine.Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches.
P50
Q24595913-102C2ED5-40B8-4F62-97A5-AD6E63BED29AQ24793543-3DD261DA-7BAF-402C-A6C4-7D9632243800Q26786375-A604563C-1ABF-4BCD-B36E-45BD8F19BE4DQ28171147-5BB8CFEA-8E4E-43B6-96B7-43B874209F12Q28186801-95616452-1492-4B83-AC2B-E877285F6492Q28216637-53B140F2-C24C-4D07-AC03-60E41C24F415Q28219024-9829315A-5C36-4C62-A24F-E3BC858FEB46Q28258825-6A951BCD-4D9B-4195-9C25-4CF853ED7387Q28285212-C66F6E36-9FEB-4A75-918A-9C2D62727621Q28286457-84CEAFF5-3F8E-4673-98D5-A85D4AFE6B46Q28296728-5FC0ED37-E03E-4B72-9DB6-ED175C7D00BDQ28301727-C255FBFF-7F3B-4B45-B1A8-C338DE362A7AQ28302049-5EB38837-894C-411C-BC48-FA0442CF3D69Q29036628-7D544D71-B191-49AC-A78D-516A78A9AC2FQ30326880-35B2342A-066E-4827-A129-F0D022E75CC4Q30430483-AAB10A0C-E378-4A3A-BA32-55984A7C348FQ30466790-3CDE434D-10F1-4699-8331-9F41910C1FD7Q30786534-8DB50723-EFDF-4FB9-8345-6272D94898EFQ33144744-CB955A02-DF7E-4FBE-9C6B-A6A7BEAA00FCQ33265796-4E314AD8-C0B8-44FC-A6C5-D7C37FBFF639Q33604494-BFEED5C1-370C-45A4-AFE4-C59917263059Q33621802-57D62D0B-2117-403F-960E-716CE90224E9Q33652269-E4C0F4E5-3CFA-414D-918F-0150CDC1A987Q33823790-BA2D4AC8-A009-4036-8CA5-E1946A42DB9FQ33831441-BC8BE831-E062-4CDB-B681-CD6C7AB6A972Q33831454-7BDC1A01-D78A-4D45-B157-74270285B3B7Q33845821-22895FD0-24DB-4AC3-BCCD-E26494961BD1Q33868502-FF1B69BD-9362-4CB8-9B94-C2F8003F3E0BQ33924857-BB3AC39D-2B61-4619-94AE-1BE52346EC82Q33925863-4D8E254A-030B-44F6-8E9C-34B72CDC9D41Q33925877-E3BA6044-6257-4CAC-A031-B152C7686686Q33925895-1A078D00-7937-4E54-B307-5A7541F142D5Q33984814-89ADC603-AAF0-4494-B289-7263BCB76C5DQ34153008-C819513F-7ACA-4F41-B097-2CFE2C4A0322Q34198968-9AD94955-FC46-49F2-AED0-54084D3BF977Q34298455-93D81568-476F-4067-99DC-1FFA33558B3BQ34417835-D6AF0371-B12E-4551-BB73-98D96EA72EF6Q34420699-4088E7FF-5C36-4394-8E46-6CEC6326ECFCQ34523930-1449F62B-6FE0-4D93-AA94-C71C854EC505Q34544624-A79D8483-1470-4B0A-BCA1-B186D4B3A1D3
P50
description
physician
@en
name
Giuseppe Nappi
@ast
Giuseppe Nappi
@en
Giuseppe Nappi
@es
Giuseppe Nappi
@nl
type
label
Giuseppe Nappi
@ast
Giuseppe Nappi
@en
Giuseppe Nappi
@es
Giuseppe Nappi
@nl
altLabel
G Nappi
@en
G. Nappi
@ast
G. Nappi
@en
G. Nappi
@es
G. Nappi
@nl
Nappi G
@en
Nappi G.
@en
Nappi
@en
prefLabel
Giuseppe Nappi
@ast
Giuseppe Nappi
@en
Giuseppe Nappi
@es
Giuseppe Nappi
@nl